{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:28:27Z","timestamp":1787045307706,"version":"build-2736575974"},"reference-count":103,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Dev. Dis.","JCDD"],"abstract":"<jats:p>Diuretics remain indispensable for the treatment of congestion in cardiovascular disease, particularly in acute and chronic heart failure. Their principal clinical value is rapid symptom relief, reduction in filling pressures and facilitation of decongestion; however, a mortality benefit has not been consistently demonstrated. This distinction is clinically important because long-term diuretic exposure in patients without objective congestion may promote hypotension, renal dysfunction, electrolyte instability, neurohormonal activation, falls, cognitive impairment and avoidable polypharmacy. The challenge is therefore not whether diuretics should be used, but how intensively, for how long and under which monitoring strategy. In this narrative review, we summarize the pharmacology of major diuretic classes, the mechanisms of diuretic resistance, and the clinical consequences of potassium, sodium and magnesium disorders. We also discuss drug interactions, frailty, chronic kidney disease, pregnancy, heart failure with preserved ejection fraction and the emerging role of sodium\u2013glucose cotransporter 2 inhibitors and adjunctive proximal-tubule strategies. A practical approach is proposed: use loop diuretics promptly when congestion is present, reassess response with symptoms, weight, urine output, renal function, electrolytes and congestion markers, and reduce or discontinue therapy once euvolemia is achieved and maintained. Deprescribing should be individualized, gradual and reversible, with explicit thresholds for restarting treatment. Optimized diuretic care requires the same discipline applied to disease-modifying heart failure therapy: phenotype recognition, dose minimization, close follow-up and avoidance of treatment inertia.<\/jats:p>","DOI":"10.3390\/jcdd13080395","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:35:08Z","timestamp":1786984508000},"page":"395","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diuretics in Cardiovascular Disease: For How Long and at What Dose?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-6411","authenticated-orcid":false,"given":"Ioannis","family":"Paraskevaidis","sequence":"first","affiliation":[{"name":"Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece"},{"name":"Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Tsougos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-2153","authenticated-orcid":false,"given":"Christos","family":"Kourek","sequence":"additional","affiliation":[{"name":"Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100828","DOI":"10.1016\/j.lanhl.2026.100828","article-title":"Guidelines and tools to assess appropriateness of diuretic prescribing and aid deprescribing: A systematic review","volume":"10","author":"Jansen","year":"2026","journal-title":"Lancet Healthy Longev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bourgeois, F.T., Olson, K.L., Tse, T., Ioannidis, J.P.A., and Mandl, K.D. (2016). Prevalence and characteristics of interventional trials conducted exclusively in elderly persons: A cross-sectional analysis of registered clinical trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155948"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10741-018-9735-7","article-title":"Loop diuretics in chronic heart failure: How to manage congestion?","volume":"24","author":"Simonavicius","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10741-020-09995-z","article-title":"Association of loop diuretics use and dose with outcomes in outpatients with heart failure: A systematic review and meta-analysis of observational studies involving patients","volume":"27","author":"Kapelios","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Blebea, N.M., Puscasu, C., Stef\u0103nescu, E., and St\u0103nigut, A.M. (2025). Diuretic therapy: Mechanisms, clinical applications, and management. J. Mind Med. Sci., 12.","DOI":"10.3390\/jmms12010026"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2215\/CJN.09630818","article-title":"Clinical pharmacology in diuretic use","volume":"14","author":"Ellison","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Aletras, G., Bachlitzanaki, M., Stratinaki, M., Foukarakis, E., Petrakis, I., Pantazis, Y., Hamilos, M., and Stylianou, K. (2026). Diuretic resistance in cardiorenal syndrome: Mechanisms, monitoring and phenotype-tailored management. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1731305"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00210-022-02228-0","article-title":"Diuretics: A contemporary pharmacological classification?","volume":"395","author":"Kehrenberg","year":"2022","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wu, L., Rodriguez, M., El Hachem, K., and Krittanawong, C. (2024). Diuretic treatment in heart failure: A practical guide for clinicians. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154470"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ejhf.3458","article-title":"Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial","volume":"27","author":"Nouhravesh","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.120.15205","article-title":"Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure","volume":"76","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bcp.16189","article-title":"The effects of diuretic deprescribing in adult patients: A systematic review to inform an evidence-based diuretic deprescribing guideline","volume":"91","author":"Paoletti","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jcpt.12372","article-title":"Effectiveness of the STOPP\/START criteria: Systematic review and meta-analysis of randomized controlled studies","volume":"41","author":"Walsh","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40266-023-01061-1","article-title":"Discontinuation of loop diuretics in older patients with chronic stable heart failure: A narrative review","volume":"40","author":"Okoye","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejim.2018.10.016","article-title":"Influence of potassium levels on one-year outcomes in elderly patients with acute heart failure","volume":"60","author":"Formiga","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jchf.2024.08.007","article-title":"Mineralocorticoid antagonism in heart failure","volume":"12","author":"Chang","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"xvag018","DOI":"10.1093\/eschf\/xvag018","article-title":"Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: A meta-analysis of randomized clinical trials","volume":"13","author":"Laborante","year":"2026","journal-title":"ESC Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejim.2025.01.014","article-title":"Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: A meta-analysis of randomized controlled trials","volume":"135","author":"Laborante","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2024.10.016","article-title":"New strategies for the treatment of hyperkalemia","volume":"132","author":"Masi","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sridharan, K., and Sivaramakrishnan, G. (2026). Safety profile of SGLT-2 inhibitors in older adults: A systematic review and network meta-analysis. Med. Sci., 14.","DOI":"10.3390\/medsci14010153"},{"key":"ref_26","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Polhuis, K.C.M.M., Wijnen, A.H.C., Sierksma, A., Calame, W., and Tieland, M. (2017). The diuretic action of weak and strong alcoholic beverages in elderly men: A randomized diet-controlled crossover trial. Nutrients, 9.","DOI":"10.3390\/nu9070660"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jchf.2017.09.023","article-title":"Integrative assessment of congestion in heart failure throughout the patient journey","volume":"6","author":"Girerd","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the ADHERE registry","volume":"149","author":"Adams","year":"2005","journal-title":"Am. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/eurheartj\/ehs444","article-title":"Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial","volume":"34","author":"Ambrosy","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Palazzuoli, A., Ruocco, G., Valente, S., Stefanini, A., Carluccio, E., and Ambrosio, G. (2022). Non-invasive assessment of acute heart failure by Stevenson classification: Does echocardiographic examination recognize different phenotypes?. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.911578"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e02","DOI":"10.15420\/cfr.2025.52","article-title":"Advances in congestion assessment in decompensated heart failure","volume":"12","author":"Ganapathy","year":"2026","journal-title":"Card. Fail. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/ejhf.1111","article-title":"How accurate is clinical assessment of neck veins in the estimation of central venous pressure in acute heart failure? Insights from a prospective study","volume":"20","author":"Breidthardt","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ejhf.825","article-title":"Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: Preliminary experience. A report from the SICA-HF study","volume":"19","author":"Pellicori","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jchf.2022.12.001","article-title":"Successful decongestion as a clinical target, performance indicator, and as a study endpoint in hospitalized heart failure patients","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e002370","DOI":"10.1161\/CIRCHEARTFAILURE.115.002370","article-title":"Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure","volume":"9","author":"Testani","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jacc.2020.12.022","article-title":"Natriuretic equation to predict loop diuretic response in patients with heart failure","volume":"77","author":"Rao","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jchf.2019.01.007","article-title":"Natriuretic response is highly variable and associated with 6-month survival: Insights from the ROSE-AHF trial","volume":"7","author":"Hodson","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2018.01.013","article-title":"First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization","volume":"203","author":"Luk","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: A pragmatic randomized trial","volume":"29","author":"Beldhuis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejim.2024.10.024","article-title":"Translating evidence into practice: Managing electrolyte imbalances and iron deficiency in heart failure","volume":"131","author":"Sato","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e004667","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss","year":"2017","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","article-title":"What is the optimal serum potassium level in cardiovascular patients?","volume":"43","author":"Macdonald","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fiorentini, D., Cappadone, C., Farruggia, G., and Prata, C. (2021). Magnesium: Biochemistry, nutrition, detection, and social impact of diseases linked to its deficiency. Nutrients, 13.","DOI":"10.3390\/nu13041136"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/jcsm.13450","article-title":"Total magnesium intake and risk of frailty in older women","volume":"15","author":"Struijk","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ackd.2018.02.010","article-title":"Magnesium and cardiovascular disease","volume":"25","author":"Tangvoraphonkchai","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Yang, Y., Chen, C., Duan, P., Thapaliya, S., Gao, L., Dong, Y., Yin, X., Yang, X., Zhang, R., and Tan, R. (2020). The ECG characteristics of patients with isolated hypomagnesemia. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.617374"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543776.2018.1523897","article-title":"Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas","volume":"28","author":"Supuran","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","article-title":"Multimorbidity in older adults with cardiovascular disease","volume":"71","author":"Forman","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ejhf.1796","article-title":"Association between loop diuretic dose changes and outcomes in chronic heart failure: Observations from the ESC-EORP Heart Failure Long-Term Registry","volume":"22","author":"Kapelios","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00392-020-01598-w","article-title":"Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction","volume":"109","author":"Martens","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/MJT.0000000000001644","article-title":"Investigation into potentially inappropriate prescribing patterns of loop diuretics in a nationally representative outpatient population","volume":"31","author":"Fosnight","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Huang, C.H., Umegaki, H., Watanabe, Y., Kamitani, H., Asai, A., Kanda, S., Nomura, H., and Kuzuya, M. (2019). Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211947"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"afaf231","DOI":"10.1093\/ageing\/afaf231","article-title":"Hospital admissions due to adverse drug reactions and adverse drug events in older adults: A systematic review","volume":"54","author":"Cosgrave","year":"2025","journal-title":"Age Ageing"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Vonna, A., Salahudeen, M.S., and Peterson, G.M. (2026). Clinical outcomes of adverse drug reaction-related hospital admissions in older adults with diabetes. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1729848"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Insani, W.N., Whittlesea, C., Alwafi, H., Man, K.K.C., Chapman, S., and Wei, L. (2021). Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252161"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Cahir, C., Curran, C., Walsh, C., Hickey, A., Brannigan, R., Kirke, C., Williams, D.J., and Bennett, K. (2023). Adverse drug reactions in an ageing population (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1029067"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000534366","article-title":"Effects of mineralocorticoid receptor antagonists for chronic kidney disease: A systematic review and meta-analysis","volume":"55","author":"Yuan","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIR.0000000000000380","article-title":"Knowledge gaps in cardiovascular care of the older adult population: A scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society","volume":"133","author":"Rich","year":"2016","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamainternmed.2020.2750","article-title":"Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy","volume":"180","author":"Nanna","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/heartjnl-2011-300692","article-title":"Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure","volume":"98","author":"Damman","year":"2012","journal-title":"Heart"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1093\/eurheartj\/ehq293","article-title":"Markers of renal function and acute kidney injury in acute heart failure: Definitions and impact on outcomes of the cardiorenal syndrome","volume":"31","author":"Lassus","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Palazzuoli, A., Ruocco, G., Severino, P., Gennari, L., Pirrotta, F., Stefanini, A., Tramonte, F., Feola, M., Mancone, M., and Fedele, F. (2021). Effects of metolazone administration on congestion, diuretic response and renal function in patients with advanced heart failure. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184207"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"F729","DOI":"10.1152\/ajprenal.00407.2020","article-title":"Salt-sensitive hypertension in chronic kidney disease: Distal tubular mechanisms","volume":"319","author":"Bovee","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1681\/ASN.2020071029","article-title":"Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR, and restores euvolemia in nondiabetic rats with induced heart failure","volume":"32","author":"Benetti","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-025-02656-1","article-title":"Circulating mitochondrial DNA signature in cardiometabolic patients","volume":"24","author":"Mengozzi","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"110522","DOI":"10.1016\/j.isci.2024.110522","article-title":"Leukocyte mitochondrial DNA copy number and cardiovascular disease: A systematic review and meta-analysis of cohort studies","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"key":"ref_80","first-page":"419","article-title":"Release of mitochondrial DNA is associated with mortality in severe acute heart failure","volume":"9","author":"Krychtiuk","year":"2020","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): A randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"ref_82","first-page":"167","article-title":"Additive diagnostic and prognostic value of bioelectrical impedance vector analysis (BIVA) to brain natriuretic peptide \u201cgrey-zone\u201d in patients with acute heart failure in the emergency department","volume":"3","author":"Lalle","year":"2014","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00392-024-02571-7","article-title":"In-hospital bioimpedance-derived total body water predicts short-term cardiovascular mortality and re-hospitalizations in acute decompensated heart failure patients","volume":"114","author":"Faragli","year":"2025","journal-title":"Clin. Res. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jchf.2019.07.008","article-title":"Lung ultrasound in acute heart failure: Prevalence of pulmonary congestion and short- and long-term outcomes","volume":"7","author":"Platz","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/ejhf.1604","article-title":"Lung ultrasound-guided treatment in ambulatory patients with heart failure: A randomized controlled clinical trial (LUS-HF study)","volume":"21","author":"Maestro","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13089-020-00163-w","article-title":"Quantifying systemic congestion with point-of-care ultrasound: Development of the venous excess ultrasound grading system","volume":"12","author":"Rola","year":"2020","journal-title":"Ultrasound J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"oeae050","DOI":"10.1093\/ehjopen\/oeae050","article-title":"Assessment of venous congestion with venous excess ultrasound score in the prognosis of acute heart failure in the emergency department: A prospective study","volume":"4","author":"Landi","year":"2024","journal-title":"Eur. Heart J. Open"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15420\/cfr.2015:24:2","article-title":"Decompensated heart failure in pregnancy","volume":"2","author":"Anthony","year":"2016","journal-title":"Card. Fail. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","article-title":"Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review","volume":"73","author":"Halpern","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.gerinurse.2023.05.009","article-title":"The association between diuretics and falls in older adults: A systematic review and meta-analysis","volume":"52","author":"Bai","year":"2023","journal-title":"Geriatr. Nurs."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjcard.2008.05.058","article-title":"Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions","volume":"102","author":"Abramov","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(87)91074-9","article-title":"Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure","volume":"2","author":"Richardson","year":"1987","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0002-9149(94)90815-X","article-title":"Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy","volume":"73","author":"Grinstead","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ejheart.2004.09.006","article-title":"Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction","volume":"7","author":"Galve","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","article-title":"Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: A double-blind, multicentre, randomized trial","volume":"40","author":"Rohde","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: The PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ejhf.2703","article-title":"Sacubitril\/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: Post-hoc analysis of EMPEROR-Reduced","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: A post hoc analysis of the EMPEROR-Preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/8\/395\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:44:31Z","timestamp":1787042671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/8\/395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":103,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcdd13080395"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13080395","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}